FDA Brief

Warning letters Drugs

FDA warning letter to

Kobayashi Healthcare International, Inc.

High riskIssued Jan 27, 2023Posted Jan 31, 2023Office of Pharmaceutical Quality

Kobayashi's Georgia plant released Zim's OTC pain drugs without microbial testing and lacked quality unit oversight, FDA says.

What happened

FDA inspected Kobayashi America Manufacturing, LLC in Dalton, Georgia, from May 23 to 27, 2022, and found the firm released over-the-counter Zim's Max Freeze gel, roll-on and liquid without testing batches for microorganisms. FDA also found the quality unit (the group responsible for batch release decisions) did not review contract manufacturer records before release, and that complaint handling was inadequate. FDA judged the firm's June 21, 2022 response inadequate, and a labeling review found the ZIM'S HYDRO COOLING PAIN RELIEF PATCH is an unapproved new drug.

What FDA found

  1. The firm released batches such as Zim's Max Freeze Roll-on lot B87695 without testing them for microorganisms, and its quality assurance director said microbial testing is not part of release testing.

    21 CFR 211.165(b)
  2. The quality unit did not review or approve production and control records from its contract manufacturer before the product was released and distributed.

    21 CFR 211.22
  3. Zim's Max Freeze S lot B77086 was relabeled for a different market without review and approval of its manufacturing, packaging and testing records.

    21 CFR 211.22
  4. The firm did not have adequate procedures for keeping and investigating customer complaints.

    21 CFR 211.22
  5. ZIM'S HYDRO COOLING PAIN RELIEF PATCH is an unapproved new drug because it does not match the allowed conditions for external analgesics: lidocaine is not permitted in a counterirritant product, and menthol at 1% is below the allowed 1.25 to 16% range.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  6. The patch is also misbranded because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA tells the firm to respond in writing within 15 working days describing corrective actions, including microbial specifications and retrospective testing of retained samples, a plan to strengthen the quality unit, and a batch-by-batch review of products now on the market. FDA also strongly recommends hiring a consultant to help meet CGMP requirements.

Who should pay attention

  • brands that buy finished OTC drug products from contract manufacturers
  • contract manufacturers and packagers making topical OTC drugs
  • retailers and distributors selling Zim's branded OTC products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  3. Auriga Research Pvt. Ltd.

    Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.

    High risk
  4. Waves and Wine, Inc.

    FDA warns Waves and Wine, a California raw pet food maker, over Listeria in its beef pet foods and inadequate food safety controls.

    High risk